SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, spinal cord injury, Parkinson's disease, Alzheimer's disease, and others; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.
View Top Employees from SanBio| Website | http://www.sanbio.com |
| Revenue | $7 million |
| Funding | $1 million |
| Employees | 16 (15 on RocketReach) |
| Founded | 2001 |
| Phone | (650) 625-8965 |
| Fax | (650) 625-8969 |
| Industry | Biotechnology, Biotechnology Research, Business Services General, Biopharma, Business Services, Pharmaceuticals, Health Care, Science and Engineering, Pharmaceutical |
| Web Rank | 29 Million |
| Competitors | BIOSENIC S.A., BlueRock Therapeutics, Kolon TissueGene, Inc., R3 Stem Cell, Xintela AB |
| SIC | SIC Code 283 Companies, SIC Code 28 Companies, SIC Code 80 Companies |
| NAICS | NAICS Code 32 Companies, NAICS Code 325 Companies, NAICS Code 54 Companies, NAICS Code 541 Companies |
Looking for a particular SanBio employee's phone or email?
SanBio Questions
The SanBio annual revenue was $7 million in 2023.
Bijan Nejadnik is the Chief Medical Officer and Head of Global Regulatory and R and D, Corporate Officer of SanBio.
15 people are employed at SanBio.
The NAICS codes for SanBio are [32, 325, 54, 541].
The SIC codes for SanBio are [283, 28, 80].
Top SanBio Employees
-
12
-
5+4
-
ViewDavid Polakovs
Director Project Management and Clinical Outsourcing at SanBio
San Francisco, California, United States22 -
2
-
1
Related Companies
